165 related articles for article (PubMed ID: 22918766)
1. (177)Lu/ (90)Y intermediate-affinity monoclonal antibodies targeting EGFR and HER2/c-neu: preparation and preclinical evaluation.
Beckford Vera DR; Eigner S; Eigner Henke K; Leyva Montaña R; Melichar F; Beran M
Recent Results Cancer Res; 2013; 194():301-17. PubMed ID: 22918766
[TBL] [Abstract][Full Text] [Related]
2. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
Razumienko EJ; Chen JC; Cai Z; Chan C; Reilly RM
J Nucl Med; 2016 Mar; 57(3):444-52. PubMed ID: 26429962
[TBL] [Abstract][Full Text] [Related]
3. Preclinical evaluation of (177)lu-nimotuzumab: a potential tool for radioimmunotherapy of epidermal growth factor receptor-overexpressing tumors.
Vera DR; Eigner S; Beran M; Henke KE; Laznickova A; Laznicek M; Melichar F; Chinol M
Cancer Biother Radiopharm; 2011 Jun; 26(3):287-97. PubMed ID: 21711096
[TBL] [Abstract][Full Text] [Related]
4. Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors.
Vera DR; Eigner S; Henke KE; Lebeda O; Melichar F; Beran M
Nucl Med Biol; 2012 Jan; 39(1):3-13. PubMed ID: 21958849
[TBL] [Abstract][Full Text] [Related]
5. Labeling anti-HER2/neu monoclonal antibodies with 111In and 90Y using a bifunctional DTPA chelating agent.
Blend MJ; Stastny JJ; Swanson SM; Brechbiel MW
Cancer Biother Radiopharm; 2003 Jun; 18(3):355-63. PubMed ID: 12954122
[TBL] [Abstract][Full Text] [Related]
6. Biodistribution and therapeutic efficacy of (125/131)I-, (186)Re-, (88/90)Y-, or (177)Lu-labeled monoclonal antibody MN-14 to carcinoembryonic antigen in mice with small peritoneal metastases of colorectal origin.
Koppe MJ; Bleichrodt RP; Soede AC; Verhofstad AA; Goldenberg DM; Oyen WJ; Boerman OC
J Nucl Med; 2004 Jul; 45(7):1224-32. PubMed ID: 15235070
[TBL] [Abstract][Full Text] [Related]
7. Radioimmunotherapy of a human lung cancer xenograft with monoclonal antibody RS7: evaluation of (177)Lu and comparison of its efficacy with that of (90)Y and residualizing (131)I.
Stein R; Govindan SV; Chen S; Reed L; Richel H; Griffiths GL; Hansen HJ; Goldenberg DM
J Nucl Med; 2001 Jun; 42(6):967-74. PubMed ID: 11390564
[TBL] [Abstract][Full Text] [Related]
8. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
[TBL] [Abstract][Full Text] [Related]
9. 177Lu-labeled antibodies for EGFR-targeted SPECT/CT imaging and radioimmunotherapy in a preclinical head and neck carcinoma model.
Liu Z; Ma T; Liu H; Jin Z; Sun X; Zhao H; Shi J; Jia B; Li F; Wang F
Mol Pharm; 2014 Mar; 11(3):800-7. PubMed ID: 24472064
[TBL] [Abstract][Full Text] [Related]
10. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to
Aghevlian S; Lu Y; Winnik MA; Hedley DW; Reilly RM
Mol Pharm; 2018 Mar; 15(3):1150-1159. PubMed ID: 29314858
[TBL] [Abstract][Full Text] [Related]
11. In vitro and in vivo characterization of 177Lu-huA33: a radioimmunoconjugate against colorectal cancer.
Almqvist Y; Steffen AC; Tolmachev V; Divgi CR; Sundin A
Nucl Med Biol; 2006 Nov; 33(8):991-8. PubMed ID: 17127172
[TBL] [Abstract][Full Text] [Related]
12. Development of Lu-177-trastuzumab for radioimmunotherapy of HER2 expressing breast cancer and its feasibility assessment in breast cancer patients.
Bhusari P; Vatsa R; Singh G; Parmar M; Bal A; Dhawan DK; Mittal BR; Shukla J
Int J Cancer; 2017 Feb; 140(4):938-947. PubMed ID: 27813061
[TBL] [Abstract][Full Text] [Related]
13. MicroSPECT/CT imaging of co-expressed HER2 and EGFR on subcutaneous human tumor xenografts in athymic mice using ¹¹¹In-labeled bispecific radioimmunoconjugates.
Razumienko E; Dryden L; Scollard D; Reilly RM
Breast Cancer Res Treat; 2013 Apr; 138(3):709-18. PubMed ID: 23525982
[TBL] [Abstract][Full Text] [Related]
14. Inactivation of HNSCC cells by 90Y-labeled cetuximab strictly depends on the number of induced DNA double-strand breaks.
Saker J; Kriegs M; Zenker M; Heldt JM; Eke I; Pietzsch HJ; Grénman R; Cordes N; Petersen C; Baumann M; Steinbach J; Dikomey E; Kasten-Pisula U
J Nucl Med; 2013 Mar; 54(3):416-23. PubMed ID: 23345302
[TBL] [Abstract][Full Text] [Related]
15. Preparation of
Pandey U; Kameswaran M; Gamre N; Dash A
J Labelled Comp Radiopharm; 2019 Apr; 62(4):158-165. PubMed ID: 30663095
[TBL] [Abstract][Full Text] [Related]
16. Radiolabeling of monoclonal anti-vascular endothelial growth factor receptor 1 (VEGFR 1) with (177)Lu for potential use in radioimmunotherapy.
Lee SY; Hong YD; Pyun MS; Felipe PM; Choi SJ
Appl Radiat Isot; 2009; 67(7-8):1185-9. PubMed ID: 19324558
[TBL] [Abstract][Full Text] [Related]
17. Enhanced efficacy of radioimmunotherapy with 90Y-CHX-A''-DTPA-hu3S193 by inhibition of epidermal growth factor receptor (EGFR) signaling with EGFR tyrosine kinase inhibitor AG1478.
Lee FT; Mountain AJ; Kelly MP; Hall C; Rigopoulos A; Johns TG; Smyth FE; Brechbiel MW; Nice EC; Burgess AW; Scott AM
Clin Cancer Res; 2005 Oct; 11(19 Pt 2):7080s-7086s. PubMed ID: 16203806
[TBL] [Abstract][Full Text] [Related]
18. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab.
Perk LR; Visser GW; Vosjan MJ; Stigter-van Walsum M; Tijink BM; Leemans CR; van Dongen GA
J Nucl Med; 2005 Nov; 46(11):1898-906. PubMed ID: 16269605
[TBL] [Abstract][Full Text] [Related]
19. (90) Y/(177) Lu-labelled Cetuximab immunoconjugates: radiochemistry optimization to clinical dose formulation.
Chakravarty R; Chakraborty S; Sarma HD; Nair KV; Rajeswari A; Dash A
J Labelled Comp Radiopharm; 2016 Jul; 59(9):354-63. PubMed ID: 27264196
[TBL] [Abstract][Full Text] [Related]
20. Combined radioimmunotherapy and chemotherapy of breast tumors with Y-90-labeled anti-Her2 and anti-CEA antibodies with taxol.
Crow DM; Williams L; Colcher D; Wong JY; Raubitschek A; Shively JE
Bioconjug Chem; 2005; 16(5):1117-25. PubMed ID: 16173788
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
